(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.
Norway OKs OTC antiviral salesTo ease response to the H1N1 pandemic, Norway is allowing over-the-counter sales of oseltamivir (Tamiflu) and zanamivir (Relenza), the Associated Press (AP) reported. The new policy starts tomorrow and is in effect until the middle of 2010. Norway has ordered 9.4 million doses of vaccine, but the manufacturer has reportedly not produced enough to meet demand.
(CIDRAP News) The World Health Organization (WHO) confirmed yesterday that it was sending a team of experts to help the government of Ukraine, where it said more than 2,300 people have been hospitalized for what is suspected to be pandemic H1N1 influenza and 38 have died.
(CIDRAP News) Questions about the tardy US supply of pandemic H1N1 vaccine have increased with the report that most of Novartis's doses may not reach the country until early in 2010 and a European regulatory recommendation that may have implications for the global vaccine supply.
(CIDRAP News) – A collection of new studies is demonstrating once again the ability of the pandemic H1N1 virus to make some people desperately sick and is raising questions about the potential strain on critical-care resources this fall and winter.